Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review
Heidelberg Pharma AG (HPHA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:
Heidelberg Pharma AG (Heidelberg Pharma) is a biopharmaceutical company that develops novel therapeutics for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, non-hodgkin lymphoma, blood cancers, generic diseases and solid tumors. Through its subsidiary Heidelberg Pharma Research GmbH provides preclinical contract research services and is the first company to develop the toxin Amanitin into oncology therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.
Heidelberg Pharma AG Key Recent Developments
Jul 08,2021: Heidelberg Pharma reports on first half-year 2021
Jan 03,2021: Heidelberg Pharma Expands Management Team
Oct 22,2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services
Oct 08,2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020
Sep 14,2020: Heidelberg Pharma receives milestone payment from Partner Magenta
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile contains critical company information including:
- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Heidelberg Pharma AG (Heidelberg Pharma) is a biopharmaceutical company that develops novel therapeutics for the treatment and specific detection of various cancers. Heidelberg Pharma’s pipeline products are focused on treating multiple myeloma, prostate cancer, hematological cancers, non-hodgkin lymphoma, blood cancers, generic diseases and solid tumors. Through its subsidiary Heidelberg Pharma Research GmbH provides preclinical contract research services and is the first company to develop the toxin Amanitin into oncology therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology platform. Heidelberg Pharma is headquartered in Ladenburg, Germany.
Heidelberg Pharma AG Key Recent Developments
Jul 08,2021: Heidelberg Pharma reports on first half-year 2021
Jan 03,2021: Heidelberg Pharma Expands Management Team
Oct 22,2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services
Oct 08,2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020
Sep 14,2020: Heidelberg Pharma receives milestone payment from Partner Magenta
Key benefits of buying this profile include:
You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
SECTION 1 - ABOUT THE COMPANY
Heidelberg Pharma AG - Key Facts
Heidelberg Pharma AG - Key Employees
Heidelberg Pharma AG - Key Employee Biographies
Heidelberg Pharma AG - Major Products and Services
Heidelberg Pharma AG - History
Heidelberg Pharma AG - Company Statement
Heidelberg Pharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Heidelberg Pharma AG - Business Description
Business Segment: ADC Technology Sales Revenue
Performance
Business Segment: Out-licensing Sales Revenue
Performance
Business Segment: Service Business Sales Revenue
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: The US
Performance
Heidelberg Pharma AG - Corporate Strategy
Heidelberg Pharma AG - SWOT Analysis
SWOT Analysis - Overview
Heidelberg Pharma AG - Strengths
Heidelberg Pharma AG - Weaknesses
Heidelberg Pharma AG - Opportunities
Heidelberg Pharma AG - Threats
Heidelberg Pharma AG - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heidelberg Pharma AG, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Jul 08, 2021: Heidelberg Pharma reports on first half-year 2021
Jan 03, 2021: Heidelberg Pharma Expands Management Team
Oct 22, 2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services
Oct 08, 2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020
Sep 14, 2020: Heidelberg Pharma receives milestone payment from Partner Magenta
Jul 09, 2020: Heidelberg Pharma reports on first half-year 2020
Apr 23, 2020: Heidelberg Pharma: Interim management statement on the first three months of 2020
Mar 19, 2020: Heidelberg Pharma announces financial figures for fiscal year 2019 and provides business update
Mar 04, 2020: Heidelberg Pharma: US patent rights granted for diagnosis and treatment of patients with TP53/RNA polymerase II deletion
Jan 22, 2020: Heidelberg Pharma secures financing commitment from its main shareholder dievini
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
Heidelberg Pharma AG - Key Facts
Heidelberg Pharma AG - Key Employees
Heidelberg Pharma AG - Key Employee Biographies
Heidelberg Pharma AG - Major Products and Services
Heidelberg Pharma AG - History
Heidelberg Pharma AG - Company Statement
Heidelberg Pharma AG - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
SECTION 2 – COMPANY ANALYSIS
Company Overview
Heidelberg Pharma AG - Business Description
Business Segment: ADC Technology Sales Revenue
Performance
Business Segment: Out-licensing Sales Revenue
Performance
Business Segment: Service Business Sales Revenue
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Germany
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: The US
Performance
Heidelberg Pharma AG - Corporate Strategy
Heidelberg Pharma AG - SWOT Analysis
SWOT Analysis - Overview
Heidelberg Pharma AG - Strengths
Heidelberg Pharma AG - Weaknesses
Heidelberg Pharma AG - Opportunities
Heidelberg Pharma AG - Threats
Heidelberg Pharma AG - Key Competitors
SECTION 3 – COMPANY FINANCIAL RATIOS
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
SECTION 4 – COMPANY’S LIFESCIENCES FINANCIAL DEALS AND ALLIANCES
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heidelberg Pharma AG, Recent Deals Summary
SECTION 5 – COMPANY’S RECENT DEVELOPMENTS
Jul 08, 2021: Heidelberg Pharma reports on first half-year 2021
Jan 03, 2021: Heidelberg Pharma Expands Management Team
Oct 22, 2020: Heidelberg Pharma contracts ProBioGen for cell line development and manufacturing services
Oct 08, 2020: Heidelberg Pharma : Interim Management Statement on the First Nine Months of 2020
Sep 14, 2020: Heidelberg Pharma receives milestone payment from Partner Magenta
Jul 09, 2020: Heidelberg Pharma reports on first half-year 2020
Apr 23, 2020: Heidelberg Pharma: Interim management statement on the first three months of 2020
Mar 19, 2020: Heidelberg Pharma announces financial figures for fiscal year 2019 and provides business update
Mar 04, 2020: Heidelberg Pharma: US patent rights granted for diagnosis and treatment of patients with TP53/RNA polymerase II deletion
Jan 22, 2020: Heidelberg Pharma secures financing commitment from its main shareholder dievini
SECTION 6 – APPENDIX
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
LIST OF TABLES
Heidelberg Pharma AG, Key Facts
Heidelberg Pharma AG, Key Employees
Heidelberg Pharma AG, Key Employee Biographies
Heidelberg Pharma AG, Major Products and Services
Heidelberg Pharma AG, History
Heidelberg Pharma AG, Subsidiaries
Heidelberg Pharma AG, Key Competitors
Heidelberg Pharma AG, Ratios based on current share price
Heidelberg Pharma AG, Annual Ratios
Heidelberg Pharma AG, Annual Ratios (Cont...1)
Heidelberg Pharma AG, Annual Ratios (Cont...2)
Heidelberg Pharma AG, Interim Ratios
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heidelberg Pharma AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
Heidelberg Pharma AG, Key Facts
Heidelberg Pharma AG, Key Employees
Heidelberg Pharma AG, Key Employee Biographies
Heidelberg Pharma AG, Major Products and Services
Heidelberg Pharma AG, History
Heidelberg Pharma AG, Subsidiaries
Heidelberg Pharma AG, Key Competitors
Heidelberg Pharma AG, Ratios based on current share price
Heidelberg Pharma AG, Annual Ratios
Heidelberg Pharma AG, Annual Ratios (Cont...1)
Heidelberg Pharma AG, Annual Ratios (Cont...2)
Heidelberg Pharma AG, Interim Ratios
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Heidelberg Pharma AG, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
LIST OF FIGURES
Heidelberg Pharma AG, Performance Chart (2016 - 2020)
Heidelberg Pharma AG, Ratio Charts
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021
Heidelberg Pharma AG, Performance Chart (2016 - 2020)
Heidelberg Pharma AG, Ratio Charts
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Heidelberg Pharma AG, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021